Should I buy or sell Oncopeptides AB (publ) stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncopeptides AB (publ) in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ONPPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONPPF, but not buy additional shares or sell existing shares. View ONPPF analyst ratings or view top-rated stocks .

How have ONPPF shares performed in 2024?

Oncopeptides AB (publ)'s stock was trading at $0.60 at the beginning of the year. Since then, ONPPF shares have increased by 0.0% and is now trading at $0.60. View the best growth stocks for 2024 here .

How do I buy shares of Oncopeptides AB (publ)?

Shares of ONPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTC:ONPPF

Oncopeptides AB (publ) (ONPPF) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ONPPF Stock Alerts

$0.60

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.60
▼
$0.60
50-Day Range: $0.60
▼
$0.60
52-Week Range: $0.60
▼
$0.60

Volume: N/A
Average Volume: 2,250 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart

Get Oncopeptides AB (publ) alerts:

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Oncopeptides AB (publ)

Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden

ONPPF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONPPF Stock News Headlines

March 6, 2024 | gurufocus.com

Oncopeptides AB (publ) - Special Call Transcript

March 6, 2024 | gurufocus.com

Oncopeptides AB (publ) To Present Updated Ocean Results Call Transcript

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

November 25, 2022 | prnewswire.com

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

November 11, 2022 | finance.yahoo.com

Oncopeptides' Pepaxti has been granted marketing authorization in the UK

November 9, 2022 | finance.yahoo.com

Oncopeptides announces the market potential for Pepaxti in Europe

November 9, 2022 | finance.yahoo.com

Oncopeptides publishes Q3 report 2022

October 26, 2022 | finance.yahoo.com

Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

October 20, 2022 | finance.yahoo.com

Issue and re-purchase of class C shares for shareholder program and incentive program

October 5, 2022 | finanznachrichten.de

Oncopeptides AB: Oncopeptides starts commercialization of Pepaxti in Europe - Germany first market

October 3, 2022 | finance.yahoo.com

Oncopeptides starts commercialization of Pepaxti in Europe - Germany first market

September 23, 2022 | finance.yahoo.com

Swedish Biotech’s Cancer Drug Fails With FDA Advisers

September 23, 2022 | finance.yahoo.com

Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC

September 23, 2022 | finance.yahoo.com

Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)

September 20, 2022 | finance.yahoo.com

Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published

September 19, 2022 | reuters.com

ONCO.ST - Oncopeptides AB | Stock Price & Latest News | Reuters

September 7, 2022 | finance.yahoo.com

Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

August 18, 2022 | finance.yahoo.com

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

August 13, 2022 | seekingalpha.com

Oncopeptides AB GAAP EPS of -SEK0.79, revenue of SEK8.8M

August 11, 2022 | finance.yahoo.com

Oncopeptides publishes Q2 report 2022

February 17, 2022 | finance.yahoo.com

Oncopeptides publishes year-end report 2021

February 14, 2022 | finance.yahoo.com

Invitation to presentation of 2021 year-end results

January 21, 2022 | finance.yahoo.com

Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time

January 13, 2022 | finance.yahoo.com

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

January 5, 2022 | prnewswire.com

Oncopeptides announces year-end cash 2021

December 10, 2021 | finance.yahoo.com

Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH

See More Headlines

Receive ONPPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncopeptides AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTC
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTC:ONPPF
CUSIP: N/A
CIK: N/A
Web: www.oncopeptides.se
Phone: 46 86 15 20 40
Fax: N/A
Employees: 57
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Jakob Lindberg Med. Lic (Age 52)
Chief Scientific Officer
Comp: $7.26M
Ms. Sofia Heigis M.Sc. (Age 44)
Chief Executive Officer
Prof. Rolf Larsson M.D.
Ph.D., Founder
Prof. Rolf Lewensohn M.D.
Ph.D., Founder
Dr. Joachim Gullbo M.D.
MSc Pharm, Ph.D., Founder
Dr. Kristina Luthman Ph.D.
Founder
Prof. Hans Ehrsson M.D.
Founder
Mr. Peter Nygren (Age 65)
Founder
Mr. Henrik Bergentoft (Age 50)
Chief Financial Officer
Ms. Eva Nordström M.Sc. (Age 54)
MSc Pharm, COO & Deputy MD

Key Competitors

View All Competitors

ONPPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncopeptides AB (publ) stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncopeptides AB (publ) in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ONPPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONPPF, but not buy additional shares or sell existing shares.
View ONPPF analyst ratings or view top-rated stocks.
How have ONPPF shares performed in 2024?: Oncopeptides AB (publ)'s stock was trading at $0.60 at the beginning of the year. Since then, ONPPF shares have increased by 0.0% and is now trading at $0.60.
View the best growth stocks for 2024 here.
How do I buy shares of Oncopeptides AB (publ)?: Shares of ONPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTC:ONPPF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncopeptides AB (publ) (ONPPF) Stock Price, News & Analysis

About Oncopeptides AB (publ)

ONPPF Stock Price History

ONPPF Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ONPPF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info